Category: Latest News
-
Nexalin shares skyrocket after Alzheimer’s study shows strong cognitive gains
Nexalin Technology Inc. (NASDAQ:NXL) shares soared 84.4% in premarket trading Wednesday after the company released positive clinical results demonstrating that its non-invasive brain stimulation therapy improved cognitive function in patients with mild Alzheimer’s disease. The study, published in Radiology, evaluated Nexalin’s proprietary 15 milliamp Gen-2 Deep Intracranial Frequency Stimulation (DIFS) system in a randomized, sham-controlled…
-
Nvidia CEO Jensen Huang says U.S. only slightly ahead of China in AI race
Nvidia (NASDAQ:NVDA) CEO Jensen Huang said on Wednesday that the United States is “not far ahead” of China when it comes to artificial intelligence development, emphasizing how quickly China is advancing in the field. The comments were made during an interview with CNBC. Huang also voiced his support for the U.S. H-1B visa program, saying…
-
Hoth Therapeutics shares climb after expanding AI partnership with NVIDIA
Hoth Therapeutics Inc. (NASDAQ:HOTH) shares rose 9.8% in premarket trading on Wednesday after the clinical-stage biopharmaceutical company announced an expansion of its artificial intelligence initiative through a new NVIDIA AI Enterprise subscription license. The company said it has secured annual NVIDIA AI Enterprise Essentials licenses to bolster its GPU-driven infrastructure, enabling advanced machine learning and…
-
Jiuzi shares surge after detailing $1 billion capital initiative
Jiuzi Holdings Inc. (NASDAQ:JZXN) stock jumped 20.2% in premarket trading on Wednesday after the Chinese company released full implementation details of its previously announced $1 billion capital plan. The company said it intends to raise the funds through a diversified capital structure, combining market financing, new commitments from existing shareholders, operational revenue, and institutional investor…
-
CervoMed shares jump after strong results in dementia drug trial
CervoMed Inc. (NASDAQ:CRVO) shares surged 9% in premarket trading on Wednesday after the clinical-stage biopharmaceutical company reported additional positive findings from its Phase 2b RewinD-LB trial, which is testing a potential treatment for dementia with Lewy bodies (DLB). The company said the new analyses showed that its investigational drug, neflamapimod, delivered notable gains in cognitive…
-
Dow Jones, S&P, Nasdaq, Futures, Wall Street set to rebound as futures edge higher; investors await Fed minutes
U.S. stock futures were slightly higher early Wednesday, signaling a potential rebound after the previous session’s pullback as investors weighed strong tech sentiment against lingering economic and political uncertainty. Nvidia (NASDAQ:NVDA) was leading premarket gains, climbing 0.7% after CEO Jensen Huang told CNBC’s Squawk Box that demand for artificial intelligence computing had grown “substantially” over…
-
Spire Global shares rise after €3 million EUMETSAT contract renewal
Spire Global Inc. (NYSE:SPIR) shares gained 2.9% in premarket trading Wednesday after the company announced it had secured a €3 million contract renewal with EUMETSAT, Europe’s meteorological satellite organization. The two-year operational contract, set to begin on August 14, 2024, extends Spire’s role in providing radio occultation (RO) data to EUMETSAT. This data offers vital…
-
PubMatic shares jump 13% after NVIDIA partnership boosts ad processing speed fivefold
PubMatic (NASDAQ:PUBM) shares surged 13% on Wednesday after the company reported a major breakthrough from its multi-year collaboration with NVIDIA (NASDAQ:NVDA), achieving ad decision processing speeds up to five times faster than traditional systems. The independent ad tech firm has fully integrated NVIDIA’s accelerated computing technology into its infrastructure, slashing inference latency from the industry…
-
TransCode Therapeutics shares surge 50% after acquiring Polynoma and securing $25 million financing
TransCode Therapeutics (NASDAQ:RNAZ) shares jumped 50% on Wednesday after the company announced the acquisition of Polynoma alongside a $25 million strategic investment from a subsidiary of CK Life Sciences. The acquisition significantly enhances TransCode’s oncology pipeline by adding Polynoma’s Phase 3-ready candidate, seviprotimut-L, a polyvalent shed antigen vaccine developed for adjuvant treatment of melanoma. At…
-
CVS Health shares slip as Amazon moves to expand pharmacy operations
CVS Health (NYSE:CVS) shares fell more than 1% in premarket trading Wednesday after Amazon (NASDAQ:AMZN) announced a major expansion of its pharmacy business. Amazon said its pharmacy division will start dispensing prescriptions for common medications through electronic kiosks located inside its One Medical primary care clinics beginning in December. The new kiosks will represent Amazon…